Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Operating Leases (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Operating Leases for 6 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 12.31% to $20.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.1 million through Dec 2025, down 12.31% year-over-year, with the annual reading at $20.1 million for FY2025, 12.31% down from the prior year.
  • Operating Leases hit $20.1 million in Q4 2025 for Bolt Biotherapeutics, down from $20.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $23.2 million in Q2 2021 to a low of $9.1 million in Q1 2021.
  • Historically, Operating Leases has averaged $19.5 million across 5 years, with a median of $20.5 million in 2022.
  • Biggest five-year swings in Operating Leases: skyrocketed 135.34% in 2022 and later fell 15.85% in 2024.
  • Year by year, Operating Leases stood at $21.9 million in 2021, then dropped by 7.48% to $20.2 million in 2022, then dropped by 13.76% to $17.4 million in 2023, then surged by 31.66% to $23.0 million in 2024, then decreased by 12.31% to $20.1 million in 2025.
  • Business Quant data shows Operating Leases for BOLT at $20.1 million in Q4 2025, $20.9 million in Q3 2025, and $21.6 million in Q2 2025.